Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Mai 2017 08:30 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy

-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study...
11. Mai 2017 09:11 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners

EMERYVILLE, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has entered into a $100 million royalty-backed note agreement with HealthCare...
09. Mai 2017 16:01 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Reports Recent Achievements and First Quarter 2017 Financial Results

EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. ...
05. Mai 2017 17:42 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Reports Inducement Grant to New Chief Operating Officer

EMERYVILLE, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Operating Officer, Richard A. King. The...
02. Mai 2017 16:06 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017

EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2017 financial results on Tuesday, May 9,...
27. April 2017 17:51 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102

EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the appointment of Richard A. King as Chief Operating Officer, reporting to Gregory...
24. April 2017 09:06 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Presents ADS-5102 Pooled Phase 3 Data Confirming Statistically Significant Reduction in Levodopa-Induced Dyskinesia and OFF Time in People with Parkinson’s Disease

-- Results presented in oral platform and poster sessions at the 69th American Academy of Neurology (AAN) Annual Meeting -- -- Results from the pooled analysis showed approximately twice as many...
18. April 2017 12:07 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Announces Oral and Poster Presentations of ADS-5102 Pooled Phase 3 Data at the 69th American Academy of Neurology Annual Meeting

EMERYVILLE, Calif., April 18, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding upcoming oral platform and poster presentations highlighting...
28. März 2017 13:38 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting

EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3...
28. März 2017 10:32 ET | Quelle: Adamas Pharmaceuticals, Inc.

Adamas to Present at the 16th Annual Needham Healthcare Conference

EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is...

Vorherige Seite